At Dr. David Macklin’s weight management practice in Toronto, patients frequently inquire about the cost of Ozempic and Wegovy, as discussions about generics have surged following the expiration of Novo Nordisk’s patent for semaglutide in Canada. The monthly costs for these medications can range from $300 to $400, prompting demand for more affordable options. Health Canada is currently reviewing nine generic versions of semaglutide, and while there is no definitive timeline for approval, estimates suggest generics may be available by summer or early fall. In India, where generics have already been approved, prices can be as low as $19 per month. The anticipated arrival of generics in Canada could significantly reduce costs and improve access for those needing these medications.
Why It Matters
The expiration of Novo Nordisk’s patent on semaglutide marks a crucial shift in the availability of weight management and diabetes medications. The high prices of Ozempic and Wegovy have limited access for many patients, making the introduction of generics a potential game changer. Historically, the patent system has allowed pharmaceutical companies to maintain monopolies on drug production, keeping prices elevated. The transition to generic versions is expected to create a more competitive market, potentially reducing monthly costs to around $100 or less, which would significantly benefit Canadians relying on these treatments for obesity and diabetes management.
Want More Context? 🔎
